Interleukin-4 blood concentrations in early and metastatic human solid neoplasms

International Journal of Biological Markers

Volumn 12, Issue 2, 1997, Pages 75-78

  Lissoni, P ^a   Merlini, D ^a   Pirato, D ^a   Meregalli, S ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Cytokines; IL 4; Solid neoplasms

Indexed keywords

INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; EARLY CANCER; FEMALE; HELPER CELL; HUMAN; LUNG CANCER; MACROPHAGE; MALE; METASTASIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SOLID TUMOR;

EID: 0030850342     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200206     Document Type: Article

References (21)

1. Atzpodien J, Kirchner H. Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 1990; 68: 1-11.
2. Lissoni P, Barni S, Rovelli F, Tancini G. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Preliminary report. Oncology 1991; 48: 125-7.
3. Lissoni P, Rovelli F, Tisi E, et al. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors. J Biol Regul Homeost Agents 1995; 9: 146-9.
4. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. J Exp Med 1982; 155: 1823-41.
5. Lamont AG, Adorini L. IL-12: a key cytokine in immune regulation. Immunol Today 1996; 17: 214-7.
6. Kishimoto T. The biolosy of interleukin-6. Blood 1989; 74: 1-10.
7. Moore KW, O'Garra A, De Waal-Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Ann Rev Immunol 1993; 11: 165-90.
8. Meffert M, Hanninen EL, Menzel T, et al. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2. Cancer Biother 1994; 9: 307-10.
9. Paul WE. Interleukin-4. A prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70.
10. Van Hal PTW, Hopstaken-Broos JPM, Prins A, et al. Potential indirect anti-inflammatory effects of IL-4. J Immunol 1994; 153: 2718-23.
11. Whitehead RP, Friedman KD, Clark DA, Pagani K, Rapp L. Phase I trial of simultaneous administration of interleukin 2 and interleukin 4 subcutaneously. Clin Cancer Res 1995; 1: 1145-52.
12. Naume B, Gately MK, Desai BB, Sundan A, Espevik T. Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation. Cytokine 1993; 5: 38-46.
13. Wigginton JM, Komschlies KL, Kuhns DB, et al. The potent antitumor activity of IL-12/pulse IL-2: role of T-cell and non-T-cell dependent mechanisms. Eur Cytokine Netw 1996; 7: 547.
14. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 1996; 88: 38-43.
15. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vitro. Eur J Immunol 1993; 23: 3043-9.
16. Brooks B, Parry H, Lawry J, Rees R. Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes. Immunology 1992; 75: 343-8.
17. Wanidworanum C, Strober W. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853-7.
18. Claasen JL, Levine AD, Buckley RH. Recombinant human IL-4 induces IgE and IgG synthesis by normal and atopic donor mononuclear cells. J Immunol 1990; 144: 2123-30.
19. Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. J Immunol 1995; 154: 3383-90.
20. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141-6.
21. Clerici M, Clerici E, Shearer GM. The tumor enhancement phenomenon: reinterpretation from a Th1/Th2 perspective. J Natl Cancer Inst 1996; 88: 461-2.